HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and...
- Presentations at the International Congress for Ataxia Research (ICAR) will feature LEXEO’s LX2006 gene therapy program for Friedreich’s ataxia...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of...
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a...
Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038NEWTON, Mass.,...
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 26, 2022...
TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science...
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a...
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November...
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel...
- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic...
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023SAN...
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor...
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s...
Enabling healthcare and life sciences enterprises to implement virtual and augmented environment for patients and clinical trialsPLEASANTON, Calif., Oct. 26,...
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...